1Cabin H S,Clubb K S,Hall C,d a1.Risk for systemic embolization of atrial fibrillation without mitral stenosis[J].Am J Cardiol,1990,65(16):1112-一1116.
2Petersen P,Godtferdsen J. Embolic complications in paroxysmal atrial fibrillation[J].Stroke,1986,17(4):622—626.
3Levy S,Breithardt G,Campbell R W, et al . Atrial fibrillation:current knowledge and recommendations for management.Working Group on Arrhythmial of the European Society of Cardiology[J]. Eur Heart J,1998,19(9) :1294-1320.
4Ricard P, Levy S, Trlgano J, et al . Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation[J]. Am J Cardiol, 1997,79(6) :815-816.
5Prystowsky E N. Management of atrial fibrillation: therapeutic options and clinical decisions [J]. Am J Cardiol, 2000, 85(10A): 3D-11D.
6Lewis R V, Mcmurray J, McDevitt D G. Effects of atenolol,verapamil,and xamoterol on heart rate and exercise tolerance in digitalized patients with chronic atrial fibrillation[J]. J Cardiovasc Pharmacol, 1989,13 ( 1 ) : 1-6.
7Kreiss Y, Sidi Y, Gur H. Efficacy and safety of intravenous amiodarone in recent onset atrial fibrillation, experience in patients admitted to a general internal medicine department[J]. Postgrad Med J, 1999,75(2) :278-281.
8Reiffel J A. Intravenous amiodarone in the management of atrial fibrillation[J]. J Cardiovase Pharmacol Ther,1999,4(4):199-204.
9Bellandi F, Cantini F, Pedone T, et al. Effectiveness of intravenous propafenone for conversion of recent--onset atrial fibrillation:a placebocontrolled study[J]. Clin Cardiol,1995,18(11):631-634.
10Fresco C, Proclemer A, Pavan A, et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized,placebo-controlled, double-blind, multicemer clinical trial.Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators[J]. Clin Cardinl. 1996. 19(5): 400-412.
